Dihexa Price Comparison — Compare 2 Vendors

View full research →
Cognitive / synaptogenesis researchSafety Rating 4/10

Price Comparison

Compare vendors · per 5mg

2 vendors competing

VendorPrice$ / mgUpdated
LeoLab Rx6/10$45.00$9.00Apr 6, 2026Buy →
Licensed Peptides8/10$129.99$13.00Jun 4, 2026Buy →

Research details

Dihexa — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeLimited clinical data; rat studies used 1.25–2 mg/kg oralsource ↗
AdministrationOral (BBB-permeable) in preclinical studies
Half-life~8–13 days (rat)
Safety4/10 · Not FDA-approved
NCAA D1Not listed

Overview

About Dihexa

Mechanism of action

HGF/MET system potentiator; derived from angiotensin IV; binds hepatocyte growth factor (HGF) and prevents its degradation; activates MET receptor; promotes synaptogenesis, dendritic spine density, and neuroplasticity; ~7 orders of magnitude more potent than BDNF per unit.

Safety profile

Limited human data. Potential: overstimulation, anxiety, insomnia at high doses. Theoretical cancer concern (HGF/MET pathway implicated in tumor growth — use with caution in cancer history). · Acts via c-Met activation — a tumor-growth pathway — giving a real oncogenicity concern; no long-term or human safety data; no human trials. Generally avoided with any cancer history.

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term stable
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Dihexa

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Dihexa is an orally active, blood-brain-barrier-permeable angiotensin IV analogue that potentiates hepatocyte growth factor (HGF) signaling at the c-Met receptor; the original 2014 JPET paper (PMID 25187433) reported it induced hippocampal spinogenesis and synaptogenesis orders of magnitude more potently than BDNF — however, this paper was formally retracted in April 2025 (PMID 40312093) due to data integrity concerns, and its primary findings should not be cited as established.
  • A 2021 Brain Sciences study independent of the retracted group found that Dihexa treatment improved spatial learning and memory in APP/PS1 Alzheimer's model mice, reduced neuroinflammatory markers, and restored neuronal populations; the beneficial effects were blocked by PI3K/AKT pathway inhibitors, identifying this axis as the operative downstream mechanism.

5 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch